CD10 and Bcl‐2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large‐cell lymphoma with very good or very poor prognoses

Biasoli, Irène; Morais, José Carlos; Scheliga, Adriana; Milito, Cristiane; Romano, Sérgio; Land, Marcelo Gerardin Poirot; Pulcheri, Wolmar; Spector, Nelson

doi:10.1111/j.1365-2559.2005.02099.x

Cited by 32 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found 71% of Bcl-2-positive tumor samples when more than 30% of the tumor cells were positive. This result was concordant with the 10/15 Bcl-2-positive PBL reported by Yoshiba et al [23] and the proportion of Bcl-2-positive DLBCLs reported in the literature [25][26][27][28][29][30][31][32][33][34][35][36]. Finally, we observed 14% of CD10 positivity suggesting a large amount of PBL of nongerminal center B-cell lymphoma (non-GCB), as shown by Yoshida et al who observed 15/ 15 non-GCB PBL [23].…”

Section: Discussionsupporting

confidence: 91%

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

et al. 2009

View full text Add to dashboard Cite

The aims of this study were to define the initial pathological and clinical characteristics, and prognostic factors of patients with primary breast malignant lymphoma (PBL). All patients treated at the Institut Curie for lymphoma with breast involvement were reviewed. A pathological review of all cases was performed. Fortyfive cases were selected in whom 38 cases were of diffuse large B-cell lymphoma. A complete analysis was then performed on these 38 patients. Twenty out of 28 cases (71%) of cases were Bcl-2 positive and four out of 28 (14%) had a CD10 positive staining. Peculiar initial characteristics showed nodal involvement in 58% of the cases and two or more extra-nodal sites in 31% of the cases. Among the 37 patients for whom all data were available, and according to the International Prognostic Index, 19 patients (51%) were classified in the low-risk group, 5 cases (14%) in the low-to intermediate-risk group, 6 patients (16%) in the intermediate-to high-risk group, and 7 (19%) case in the high-risk group. At the end of initial therapy, 34 patients (89%) achieved CR. With a median follow-up of 96 months, 18 patients (47%) relapsed of whom 3 had a relapse in central nervous system site. The 5-year disease-free (DFS) and overall survivals (OS) were 54% and 61%, respectively. In multivariate analysis, the presence of 2 or more extranodal sites was prognostic for lower DFS (P 5 0.0008) and OS (P 5 0.09), and a performance status ‡1 was prognostic for lower OS (P 5 0.005). Finally, when our series was compared with a historical series of 111 patients with aggressive nodal lymphomas, we observed significant lower survival rates in localized PBL (P < 0.03). Initial breast localization has a pejorative impact on the outcome of patients with Non-Hodgkin's Lymphoma (NHL), with an impressive adverse influence of additional extranodal sites. These results suggest a specific management of NHL with breast involvement. Am. J. Hematol. 84:133-139, 2009. V

show abstract

Section: Discussionsupporting

confidence: 91%

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In the multivariate survival analysis, older age, the presence of B-symptoms, abnormal serum LDH, more advanced clinical stage (III/IV), and TIMP-1 expression were related to poorer overall survival in the patients with diffuse large B-cell lymphoma. This result is in agreement with those of previous studies of diffuse large B-cell lymphoma using tissue microarray, [59][60][61][62] reflecting the reliability and robustness of our data. Therefore, TIMP-1 expression is an independent factor, and represents a marker for poor prognosis with potential therapeutic implications.…”

Section: Discussionsupporting

confidence: 93%

Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma

Choi

Lee

et al. 2006

Modern Pathology

View full text Add to dashboard Cite

The tissue inhibitor of metalloproteinase-1 (TIMP-1) is a stromal factor that promotes plasmablastic differentiation, and the survival of germinal center B-cells. The expression of TIMP-1 is known to be correlated with a subset of non-Hodgkin lymphoma at the mRNA level, and Epstein-Barr virus infection in vitro. To characterize TIMP-1( þ ) diffuse large B-cell lymphoma, TIMP-1 expression was investigated in tissue microarrays from 182 cases of de novo diffuse large B-cell lymphoma and compared with prognostic factors, immunophenotypes, and Epstein-Barr virus infection status. TIMP-1 was expressed not only in tumor cells themselves, in 14 of 182 cases (8%), designated as TIMP-1( þ ) diffuse large B-cell lymphoma, but also in stromal cells like fibroblasts and endothelial cells. In univariate analysis and hierarchical clustering, our findings suggest that TIMP-1 expression may represent a distinct subgroup. In multivariate analysis, TIMP-1( þ ) diffuse large B-cell lymphoma (n ¼ 14) was associated with unfavorable outcomes compared to TIMP-1(À) diffuse large B-cell lymphoma (n ¼ 168) (odds ratio ¼ 2.5, P ¼ 0.049). Together with TIMP-1 expression, age (greater than 60 years), the presence of B-symptoms, abnormal lactate dehydrogenase level, or more advanced stage (III/IV) was correlated with a poor overall survival. However, TIMP-1 expression in diffuse large B-cell lymphoma was not correlated with other prognostic factors including: clinical stage, international prognostic index score, and nongerminal center B-cell phenotype, as well as Epstein-Barr virus infection. Our results suggest that TIMP-1 expression may be an independent negative prognostic factor in patients with diffuse large B-cell lymphoma.

show abstract

“…Regarding the prognostic value of Bcl-2 expression in DLBCLs, most studies have shown no difference in prognosis between Bcl-2 positive and negative patients, whereas a recent study by Biasoli et al suggested that Bcl-2 expression, especially in the high IPI group, is associated with a significantly decreased survival (8,22,28,29). Our results show no difference in survival between Bcl-2 positive and negative groups, similar to the results of most previous studies, except for Biasoli et al (22).…”

Section: A B C D Ementioning

confidence: 99%

Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by Immunohistochemical Profiles with Emphasis on CD138 Expression as a Poor Prognostic Factor

Park

2006

J Korean Med Sci

View full text Add to dashboard Cite

CD10 and Bcl‐2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large‐cell lymphoma with very good or very poor prognoses

Abstract: The expression of CD10 in the low-risk IPI group, and the expression of Bcl-2 in the high-risk IPI group can identify two subgroups of patients who might benefit from new risk-adaptive treatment approaches.

Cited by 32 publications

References 22 publications

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma

Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by Immunohistochemical Profiles with Emphasis on CD138 Expression as a Poor Prognostic Factor

Contact Info

Product

Resources

About